Global /Canada /Healthcare /Drug Manufacturers - General /APLI

Appili Therapeutics Inc.

APLI

• TSX: APLI • Delayed

0.0200CAD 0%

0.0143 USD

As of 7 June 2026, Appili Therapeutics Inc. has a market cap of $1.9M USD, ranking #47297 globally and #2470 in Canada. It ranks #4198 in the Healthcare sector, and #1330 in the Drug Manufacturers - General industry.

Global Rank

47297

Country Rank

2470

Sector Rank

4198

Industry Rank

1330

Key Stats

Market Cap

$1.9MUSD

2.65M CAD

Enterprise Value

$10.68MUSD

14.9M CAD

Revenue (TTM)

$147.9KUSD

206.31K CAD

EBITDA (TTM)

-$4.42MUSD

-6.16M CAD

Net Income (TTM)

-$2.12MUSD

-2.96M CAD

PS Ratio

12.8

PB Ratio

-0.2

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Donald Cilla open_in_new

Employees

Founded

2015

Website

appilitherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	33%	0%	-25%	-33%	-20%	-33%	-50%	-98%

Upcoming Earnings

Earnings Date

Tue, Jun 23

News

Markets

Exchange	Ticker	Price	Quotes
Toronto Stock Exchange (TSX) MIC: XTSE PRIMARY	APLI Appili Therapeutics Inc Ordinary Shares ISIN: CA03783R1073 Shares Out.: Shares Outstanding: 128.366M¹ Shares Float: 113.932M² TV: TradingView: TSX: APLI SA: Stock Analysis: TSX: APLI YF: Yahoo Finance: APLI.TO GF: Google Finance: TSE: APLI BA: Barron's: APLI MS: Morningstar: XTSE: APLI	0.0200 CAD	TV: TradingView: TSX: APLI SA: Stock Analysis: TSX: APLI YF: Yahoo Finance: APLI.TO GF: Google Finance: TSE: APLI BA: Barron's: APLI MS: Morningstar: XTSE: APLI
Cboe Canada (NEO) MIC: NEOE	APLI Appili Therapeutics Inc Ordinary Shares ISIN: CA03783R1073 TV: TradingView: NEO: APLI SA: Stock Analysis: NEO: APLI YF: Yahoo Finance: APLI.NE GF: Google Finance: NEO: APLI BA: Barron's: APLI MS: Morningstar: NEOE: APLI	0.0200 CAD	TV: TradingView: NEO: APLI SA: Stock Analysis: NEO: APLI YF: Yahoo Finance: APLI.NE GF: Google Finance: NEO: APLI BA: Barron's: APLI MS: Morningstar: NEOE: APLI
OTC Markets (OTCMKTS / OTC) MIC: OTCM	APLIF Appili Therapeutics Inc Ordinary Shares ISIN: CA03783R1073 Shares Out.: Shares Outstanding: 121.266M¹ Shares Float: 106.832M² TV: TradingView: OTC: APLIF SA: Stock Analysis: OTC: APLIF YF: Yahoo Finance: APLIF GF: Google Finance: OTCMKTS: APLIF BA: Barron's: APLIF MS: Morningstar: PINX: APLIF	0.0130 USD	TV: TradingView: OTC: APLIF SA: Stock Analysis: OTC: APLIF YF: Yahoo Finance: APLIF GF: Google Finance: OTCMKTS: APLIF BA: Barron's: APLIF MS: Morningstar: PINX: APLIF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Appili Therapeutics Inc.

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Similar Companies

Industry: Drug Manufacturers - General (Canada)

Name	Market Cap (USD) diff.	PE	Country
Xenon Pharmaceuticals Inc. NASDAQ: XENE	$5.39B 284K%	-	Canada
Knight Therapeutics Inc. TSX: GUD	$519.8M 725.1M CAD 27K%	-	Canada
Milestone Pharmaceuticals Inc. NASDAQ: MIST	$223.22M 12K%	-	Canada
Satellos Bioscience Inc. TSX: MSCL	$155.46M 216.85M CAD 8K%	-	Canada
BioSyent Inc. TSXV: RX	$118.9M 165.86M CAD 6K%	18.5	Canada
Helix BioPharma Corp. TSX: HBP	$110.6M 154.28M CAD 6K%	-	Canada

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 40M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 29M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 19M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 17M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 15M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 15M%	20.5	Switzerland

chevron_leftBack